Astrazeneca Share News (AZN)

LONDON BROKER RATINGS: Jefferies cuts Aston Martin to 'underperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Did markets overreact to U.S. CPI? Maybe

STOXX 600 up 0.15%

*

FTX's fall is bolstering traditional risk assets

STOXX 600 up 0.15%

*

TOP NEWS: AstraZeneca receives three recommendations for EU approval

(Alliance News) - AstraZeneca PLC on Monday said in won three recommendations for approval for the treatment of adults with cancers in the European Union from the Committee for Medicinal Products for Human Use of the European Medicines Agency.

LONDON BROKER RATINGS: Credit Suisse cuts Ferrexpo to 'neutral'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

LONDON MARKET OPEN: Informa lifts FTSE 100; pound above USD1.18

(Alliance News) - Stocks in London were mostly lower on Monday, though the FTSE 100 was in the green as investors looked ahead to the UK budget statement later in the week, which Chancellor Jeremy Hunt promised to be "rabbit-free".

Three AstraZeneca drugs recommended for EU approval

(Sharecast News) - AstraZeneca announced on Monday morning that three of its drugs had been recommended for approval in the European Union.

GSK's oncology business suffers fresh blow with Zejula setback

News follows setback to GSK's blood cancer drug Blenrep

*

TOP NEWS: AstraZeneca wins US FDA approval for lung cancer drugs

(Alliance News) - AstraZeneca PLC on Friday said the US Food & Drug Administration has approved its cancer drugs Imfinzi and Imjudo in combination with chemotherapy for the treatment of adults with stage four non-small cell lung cancer.

AstraZeneca's Imfinzi gets FDA approval for lung cancer treatment

(Sharecast News) - AstraZeneca on Friday said its Imfinzi drug in combination with the Imjudo antibody and platinum-based chemotherapy has been approved in the US for the treatment of adult patients with stage IV non-small cell lung cancer.

UK stocks notch two-month highs as U.S. inflation cools

AstraZeneca jumps on raising earnings forecast

*

Much of biopharma industry yet to set climate impact targets - report

LONDON, Nov 9 (Reuters) - Much of the global pharmaceutical and biotech industry has yet to set any targets for reducing carbon emissions in line with the Paris Agreement, a new analysis has found, despite the biggest companies in the sector leading the way.

AstraZeneca lifts 2022 earnings outlook as cancer drugs boost results

Co sees sales growth in China, despite expecting a decline - CEO

*

TOP NEWS: AstraZeneca swings to third-quarter profit and ups guidance

(Alliance News) - AstraZeneca PLC on Thursday said it was continuing to see the benefit of sustained investment, as it raised its annual guidance on the back of strong results in the year to date.

STOXX dips

STOXX 600 down 0.2%

*